New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:11 EDTINFIInfinity Pharmaceuticals sees 2013 net loss $115M-$125M
Consensus for FY13 EPS is ($3.04). The company said it entered 2013 with approximately $327M in cash and investments. Infinity expects operating expenses for 2013 to range from $115M-$125M, net loss for 2013 to range from $115M-$125M and expects to end 2013 with a year-end cash and investments balance ranging from $210M-$220M. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation provides a cash runway into 2015, the company said.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:31 EDTINFIInfinity Pharmaceuticals reports results from Phase 1 study of duvelisib
Infinity Pharmaceuticals reported updated data from a Phase 1 monotherapy study of duvelisib, an inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma, a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72%, including a 33% complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma.
December 8, 2014
10:47 EDTINFIInfinity reports updated Phase 1 data from duvelisib study, says well tolerated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use